Fibroblast growth factor 21 (FGF21) analogs are in development for metabolic dysfunction‐associated steatotic liver disease (MASLD), but their impact on problematic alcohol use (PAU), alcohol use disorder (AUD), binge drinking, and alcohol‐related liver disease (ARLD) is unknown.
Journal of Hepatology published a clinical update in Research Highlights on 24 Feb 2026.
The item focuses on Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol‐related liver disease.
Review the original article for the full source wording and details.